Home › Trials › NCT07033026

NGM120 treatment for cachexia in colorectal cancer

A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia

Phase 2 Interventional NGM Biopharmaceuticals, Inc · NCT07033026

This trial tests whether the drug NGM120 can help people with colorectal cancer who have cancer cachexia gain or maintain weight and improve symptoms.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment136 (estimated)
Ages18 Years and up
SexAll
SponsorNGM Biopharmaceuticals, Inc Industry-sponsored
Locations28 sites (Los Angeles, California and 27 other locations)
Trial IDNCT07033026 on ClinicalTrials.gov

What this trial studies

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial testing NGM120 in people with colorectal cancer who have cancer cachexia. Participants are randomized to receive NGM120 every 4 weeks, NGM120 every 8 weeks, or placebo, with treatment and follow-up visits to measure efficacy, safety, and tolerability. Key eligibility includes an active diagnosis of colorectal cancer and cachexia defined by the Fearon criteria, while exclusions include reversible causes of poor intake and current tube or parenteral feeding. Study sites are operated by NGM Biopharmaceuticals and are located in California, requiring in-person visits for dosing and monitoring.

Who should consider this trial

Good fit: Ideal candidates are adults with active colorectal cancer who meet the Fearon criteria for cachexia, can give informed consent, and are not receiving tube feedings or parenteral nutrition.

Not a fit: Patients with reversible causes of poor food intake, those on tube feedings or parenteral nutrition, or those whose cachexia is due to other non-cancer causes are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, NGM120 could help patients with colorectal cancer-related cachexia preserve or regain weight and improve physical function and quality of life.

How similar studies have performed: Previous pharmacologic approaches to cancer cachexia have shown limited but sometimes encouraging results, and NGM120 represents a relatively novel candidate being tested in this space.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Documented active diagnosis of colorectal cancer.
2. Cachexia defined by Fearon criteria of weight loss.
3. Signed informed consent.

Exclusion Criteria:

1. Current active reversible causes of decreased food intake.
2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
3. Have cachexia caused by other reasons.

Where this trial is running

Los Angeles, California and 27 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Colorectal CancerCRCCancer Cachexia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.